0%
Print report
Variant interpretation report

BRCA2 c.10111A>G, p.(Thr3371Ala)

NM_000059.4:c.10111A>G NP_000050.3:p.(Thr3371Ala) Missense · exon 27 View identifiers
Classification
Uncertain significance

Variant description:

No variant summary was recorded for this case.

Five-step scale from benign to pathogenic. This variant is uncertain. Select a step to read what it means.

Uncertain.The recorded classification is uncertain significance.

In plain language

Gene-level background from the recorded interpretation.

About BRCA2

BRCA2 encodes a DNA repair protein that maintains genome stability by repairing double-strand breaks through homologous recombination and by protecting DNA replication forks. It acts as a tumor suppressor, and inherited loss-of-function changes cause hereditary breast and ovarian cancer syndrome, with elevated lifetime risks of breast, ovarian, prostate, and pancreatic cancers; biallelic changes cause Fanconi anemia complementation group D1. Reduced or altered BRCA2 activity is implicated in multiple tumor types, and PARP inhibitors are an approved treatment for BRCA2-associated ovarian and breast cancers.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is ClinGen BRCA2 VCEP v1.2. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 0 Benign evidence criteria: 0
Pathogenic criteria applied · 0

No pathogenic criterion marked as applied in the recorded assessment.

Benign criteria applied · 0

No benign criterion marked as applied in the recorded assessment.

Recorded classification: Uncertain significance

VUS: under the ENIGMA BRCA1/2 v1.2 rules no criterion was met, and the zero point score falls in the -1 to 5 VUS band. Flagged for human review: most criteria could not be evaluated from the available evidence, so this classification may change.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

gnomAD v4.1
gnomAD v2.1
Population frequency
17 / 1,614,084 alleles

gnomAD v4.1: 17 / 1,614,084 alleles. Recorded AF 1.05323e-05. Recorded homozygote count 0.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 7.07504e-06; MAF= 0.00071%, 2/282684 alleles, homozygotes = 0) and has highest observed frequency in the East Asian population (AF= 0.000100241; MAF= 0.01002%, 2/19952 alleles, homozygotes = 0).

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 0.00043426338074041906, 8/18422 alleles, homozygotes = 0).

No screenshot for this evidence
REVEL score
0.093 recorded score

Recorded REVEL score: 0.093. Refer to the recorded PP3/BP4 rationale for interpretation.

No listed criterion applied
ClinVar submissions
13 reported laboratory submissions

9 Likely benign · 2 Uncertain significance · 2 Benign. ClinVar API review status: criteria provided, multiple submitters, no conflicts.

Context only ClinVar ↗
Functional evidence
Statement recorded

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. BRCA2, a tumor suppressor involved in the DNA damage response, is mutated in various cancer types.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
2 recorded samples

This variant has previously been reported in somatic cancers (COSMIC; COSV116004818, n = 2 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under ClinGen BRCA2 VCEP v1.2, with the data and sources behind each one.

28 criteria with recorded statuses: 0 met · 0 not met · 26 not assessed · 2 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

Governing framework: ClinGen ENIGMA BRCA1/BRCA2 Expert Panel specification v1.2 (cspec), the applicable VCEP for BRCA2; generic ACMG/AMP not used because an applicable gene-specific specification exists.

PS2 and PM6: declared Not Applicable by the ENIGMA v1.2 specification for BRCA2 because BRCA1/2-related cancers occur relatively commonly and there is no information to calibrate the predictive capacity of de novo occurrences; neither criterion is scored. Case data are consistent: no de novo or parental-testing evidence exists for c.10111A>G.

PP1 and BS4: ENIGMA requires a quantitative co-segregation likelihood ratio for both codes. For BRCA2 c.10111A>G p.(Thr3371Ala) the Segregation LR cell is blank in the ENIGMA multifactorial dataset (Parsons et al. 2019 SuppT1), and no publication reports segregation or non-segregation in affected relatives (only variant-mentioning paper, PMID:27376475, is a single-proband validation cohort report). With no informative meioses in either direction, PP1 and BS4 are not assessable and are returned not_assessed; the non-blank family-history LR (7.10) and co-occurrence LR (1.51) components are multifactorial clinical-data evidence for the PP4/BP5 domain, not segregation, and were not used here.

No segregation or de novo criterion was inferred from any other source's final classification (e.g., ClinVar Likely benign submissions or IARC posterior probability were not used as evidence for this group).

Not assessed · 26 · no assessment recorded

PVS1 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

PVS1 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file
PS1 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

PS1 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file
PS3 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

PS3 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file
PS4 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

PS4 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file
PM1 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

PM1 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file
PM2 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

PM2 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file
PM3 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

PM3 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file
PM4 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

PM4 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file
PM5 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

PM5 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file
PP1 Not assessed: no co-segregation data were available; the ENIGMA multifactorial dataset records no segregation likelihood ratio for this variant. Details ▾Hide ▴
Reasoning

Under the ENIGMA BRCA1/2 v1.2 specification, PP1 is applicable only as a quantitative co-segregation likelihood ratio (PP1 Supporting LR >= 2.08:1, Moderate >= 4.3:1, Strong >= 18.7:1, Very Strong >= 350:1; LR between 0.48 and 2.08 provides no supporting evidence in either direction). The ENIGMA multifactorial dataset (Parsons et al. 2019, HUMU-40-1557-s001 SuppT1) contains an exact-match row for BRCA2 c.10111A>G p.(Thr3371Ala), but its Segregation LR cell is blank, meaning no co-segregation data contributed to the model; the non-blank Co-occurrence LR (1.51) and Family History LR (7.10) components are clinical-history/co-occurrence evidence (PP4/BP5 domain), not segregation. No retrieved publication reports segregation of this variant in affected relatives. With no segregation LR or informative meioses available, PP1 cannot be scored (neither met nor refuted), so it is returned not_assessed pending segregation data.

Rule
ENIGMA BRCA1/2 v1.2 PP1: co-segregation in multiple affected family members measured by quantitative co-segregation analysis; PP1 Supporting LR >=2.08:1, Moderate LR >=4.3:1, Strong LR >=18.7:1, Very Strong LR >=350:1 (Appendix I).
Evidence considered
  • ENIGMA BRCA1/2 v1.2 CSPEC PP1 rule: 'Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease, as measured by a quantitative co-segregation analysis method' with Bayes-score weights PP1 LR >=2.08:1 (Supporting), >=4.3:1 (Moderate), >=18.7:1 (Strong), >=350:1 (Very Strong); instructions add that LR >0.48 and <2.08 provides no supporting evidence in either direction.
  • Parsons et al. 2019 multifactorial likelihood table (vcep_humu_40_1557_s001, SuppT1, exact variant match) lists BRCA2 c.10111A>G p.(Thr3371Ala) with a blank Segregation LR cell; only Co-occurrence LR 1.51 and Family History LR 7.10 contribute to the combined LR, i.e., the multifactorial model contains no segregation component for this variant.
  • SuppT2 of the same source attributes the c.10111A>G data points to the Easton et al. 2007 dataset, but no cosegregation likelihood ratio for the variant is reported in any retrieved VCEP table or paper.
  • PMID:27376475, the only retrieved publication that mentions c.10111A>G, reports the variant in a single heterozygous proband from an NGS validation cohort and contains no family segregation analysis.
Still missing
  • No quantitative co-segregation LR for c.10111A>G is available: the Segregation LR cell is empty in Parsons et al. 2019 SuppT1 and no ENIGMA reference-set (Supplementary Table 7) row or publication reporting segregation in affected family members was found.
  • Segregation analysis (number of affected carriers/non-carriers and meioses, computed via COOL or CAL-Leiden per ENIGMA Appendix I) would be required before PP1 can be applied.
Sources
cspec ↗vcep_humu_40_1557_s001PMID:27376475 ↗
PP2 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

PP2 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file
PP3 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

PP3 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file
PP4 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

PP4 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file
PP5 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

PP5 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file
BA1 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

BA1 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file
BS1 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

BS1 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file
BS2 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

BS2 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file
BS3 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

BS3 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file
BS4 Not assessed: no non-segregation data were available; no segregation likelihood ratio or affected non-carriers are reported for this variant. Details ▾Hide ▴
Reasoning

Under the ENIGMA BRCA1/2 v1.2 specification, BS4 requires demonstrated lack of segregation in affected family members quantified as a co-segregation likelihood ratio (BS4 Supporting LR <= 0.48:1, Moderate <= 0.23:1, Strong <= 0.05:1, Very Strong <= 0.00285:1; LR between 0.48 and 2.08 provides no supporting evidence in either direction). No such data exist for c.10111A>G: the Segregation LR cell for the variant is blank in the ENIGMA multifactorial dataset (Parsons et al. 2019 SuppT1), no affected non-carrier observations or non-segregation LR are reported in any retrieved source, and the only variant-mentioning publication (PMID:27376475) is a single-proband report with no family studies. A blank segregation LR is the absence of segregation data, not evidence of lack of segregation, so BS4 cannot be scored and is returned not_assessed pending non-segregation data.

Rule
ENIGMA BRCA1/2 v1.2 BS4: lack of segregation in affected family members measured by quantitative co-segregation analysis; BS4 Supporting LR <=0.48:1, Moderate LR <=0.23:1, Strong LR <=0.05:1, Very Strong LR <=0.00285:1 (Appendix I).
Evidence considered
  • ENIGMA BRCA1/2 v1.2 CSPEC BS4 rule: 'Lack of segregation in affected members of a family, as measured by a quantitative co-segregation analysis method' with Bayes-score weights BS4 Supporting LR <=0.48:1, Moderate <=0.23:1, Strong <=0.05:1, Very Strong <=0.00285:1; instructions add that LR >0.48 and <2.08 provides no supporting evidence in either direction (PP1 and BS4 not applicable in the neutral zone).
  • Parsons et al. 2019 SuppT1 (vcep_humu_40_1557_s001) exact-match row for BRCA2 c.10111A>G p.(Thr3371Ala) shows a blank Segregation LR cell; absence of a segregation LR must not be read as evidence of lack of segregation.
  • PMID:27376475, the only retrieved publication mentioning c.10111A>G, reports a single heterozygous HBOC proband with no segregation or non-segregation family data.
Still missing
  • No segregation or non-segregation data for c.10111A>G: no affected relatives genotyped, no affected non-carriers reported, and no quantitative LR <=0.48 available from ENIGMA datasets or the literature.
  • Family studies showing affected members who do not carry the variant (or a computed BS4 LR) would be required to apply BS4.
Sources
cspec ↗vcep_humu_40_1557_s001PMID:27376475 ↗
BP1 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

BP1 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file
BP2 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

BP2 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file
BP3 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

BP3 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file
BP4 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

BP4 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file
BP5 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

BP5 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file
BP6 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

BP6 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file
BP7 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

BP7 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file
Not applicable · 2· recorded as not applicable Show reasons ▾Hide reasons ▴
PS2 VCEPNot applicable: the ENIGMA BRCA1/2 v1.2 specification does not use de novo evidence when classifying BRCA2 variants. Details ▾Hide ▴
Reasoning

The governing framework is the ClinGen ENIGMA BRCA1/BRCA2 Expert Panel specification v1.2 (CSPEC record for BRCA2), which declares PS2 (de novo, both maternity and paternity confirmed) 'Not applicable' for BRCA2. Its instructions state: 'BRCA1/2-related cancers occur relatively commonly. No information to calibrate the predictive capacity of de novo occurrences.' Because the VCEP explicitly does not use de novo occurrence evidence for BRCA1/2 classification, PS2 is not applied here regardless of any case data. Consistently, no de novo occurrence is reported anywhere in the case bundle: the only publication mentioning the variant (PMID:27376475) reports it as a heterozygous missense change in 1 of 240 prospective HBOC probands with no parental testing or de novo analysis, and no ClinVar submission or other source reports proband/parent testing results.

VCEP rule
ENIGMA BRCA1/2 v1.2 specification: PS2 applicability = Not Applicable for BRCA2 (no calibrated predictive value for de novo occurrences in BRCA1/2-related cancers).
Evidence considered
  • ClinGen ENIGMA BRCA1/BRCA2 v1.2 CSPEC (cspec) marks PS2 as 'Not applicable' for BRCA2, with instructions: 'BRCA1/2-related cancers occur relatively commonly. No information to calibrate the predictive capacity of de novo occurrences.'
  • No proband/parental trio or de novo evidence exists in the case bundle; PMID:27376475 (only variant-mentioning publication) reports BRCA2 c.10111A>G p.Thr3371Ala as a heterozygous finding in a single HBOC proband with no parental testing.
Still missing
  • No parental testing or de novo occurrence data exist for c.10111A>G; under the ENIGMA VCEP this is moot because PS2 is not applicable to BRCA2, but such data would be required if a generic framework were ever applied.
Sources
PM6 VCEPNot applicable: the ENIGMA BRCA1/2 v1.2 specification does not use assumed de novo evidence for BRCA2 variants. Details ▾Hide ▴
Reasoning

The governing ClinGen ENIGMA BRCA1/BRCA2 Expert Panel specification v1.2 declares PM6 (assumed de novo, without confirmation of paternity and maternity) 'Not applicable' for BRCA2, with the instruction: 'BRCA1/2-related cancers occur relatively commonly. No information to calibrate the predictive capacity of de novo occurrences.' PM6 is therefore not used for BRCA2 variant classification in this framework. No case evidence would alter this: there is no report of an assumed de novo occurrence or of unconfirmed parental testing for c.10111A>G in any retrieved source.

VCEP rule
ENIGMA BRCA1/2 v1.2 specification: PM6 applicability = Not Applicable for BRCA2 (no calibrated predictive value for de novo occurrences in BRCA1/2-related cancers).
Evidence considered
  • ClinGen ENIGMA BRCA1/BRCA2 v1.2 CSPEC (cspec) marks PM6 as 'Not applicable' for BRCA2, with instructions: 'BRCA1/2-related cancers occur relatively commonly. No information to calibrate the predictive capacity of de novo occurrences.'
  • No source in the case bundle reports an assumed de novo occurrence or parental testing results for c.10111A>G; the only variant-mentioning paper (PMID:27376475) describes a single heterozygous carrier with no family or parental testing data.
Still missing
  • No proband/parental genotyping results are available for c.10111A>G; per the ENIGMA VCEP, PM6 is not applicable to BRCA2 regardless.
Sources

Identifiers

Gene
BRCA2
Transcript
NM_000059.4
Coding (HGVS c.)
NM_000059.4:c.10111A>G
Protein (HGVS p.)
NP_000050.3:p.(Thr3371Ala)
GRCh38
chr13:32398624 A>G
GRCh37
chr13:32972761 A>G
Location and type
Exon 27 · missense
ClinVar
37720
COSMIC
COSV116004818

Gene diagram

Every interpreted variant in BRCA2, mapped onto the exon structure of NM_000059.4. Select a row to find it on the plot.

BRCA2NM_000059.4
Fetching transcript structure from UCSC…
gnomAD v4.1 17 / 1,614,084 alleles AF 1.05e-05 · 0 homozygotes · FAF 0.000104
gnomAD v2.1 2 / 282,684 alleles AF 7.08e-06 · 0 homozygotes
gnomAD-Canada v1.0 Allele count data not recorded

By genetic ancestry

gnomAD v4.1

AF 1.1e-05 · 17 / 1,614,084 alleles · 0 hom · FAF 0.0001
East Asian9 / 44,898 0.0002
Remaining individuals8 / 62,486 0.00013
0 alternate alleles recorded in 8 other groups: Admixed American, European (Finnish), Amish, Middle Eastern, South Asian, Ashkenazi Jewish, African/African American, European (non-Finnish).

gnomAD v2.1

AF 7.1e-06 · 2 / 282,684 alleles · 0 hom
East Asian2 / 19,952 0.0001
0 alternate alleles recorded in 7 other groups: African/African American, Admixed American, Ashkenazi Jewish, European (Finnish), European (non-Finnish), Remaining individuals, South Asian.

gnomAD-Canada

AF not recorded · ? / ? alleles

Statements

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 1.05323e-05; MAF= 0.00105%, 17/1614084 alleles, homozygotes = 0) and has highest observed frequency in the East Asian population (AF= 0.000200454; MAF= 0.02005%, 9/44898 alleles, homozygotes = 0); grpmax FAF= 0.00010391.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 7.07504e-06; MAF= 0.00071%, 2/282684 alleles, homozygotes = 0) and has highest observed frequency in the East Asian population (AF= 0.000100241; MAF= 0.01002%, 2/19952 alleles, homozygotes = 0).

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 0.00043426338074041906, 8/18422 alleles, homozygotes = 0).

Open the gnomAD-Canada detail page →

SpliceAI and Pangolin

SpliceAI acceptor lossat -38 bp
0.048
SpliceAI acceptor gainat -374 bp
0.003
SpliceAI donor lossat -265 bp
0.000
SpliceAI donor gainat +361 bp
0.000
Pangolin splice lossmagnitude shown
-0.103
Pangolin splice gain
0.002

Other predictors

REVEL
0.093
BayesDel
-0.538

How the predictions were used

PP3 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

PP3 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file
BP4 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

BP4 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file
BP7 Not assessed: insufficient evidence was available to evaluate this criterion. Details ▾Hide ▴
Reasoning

BP7 could not be assessed because its agent did not produce valid output.

Still missing
  • attempt 1: Hermes timed out after 200s and left no usable output_file
  • attempt 2: Hermes timed out after 200s and left no usable output_file
  • attempt 3: Hermes timed out after 200s and left no usable output_file

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.05). REVEL score = 0.093. BayesDel score = -0.538317.

9 paper records listed. No publication is explicitly linked to an applied criterion in the recorded metadata.

Recorded publications

  • Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study.
    Borg A et al. · 2010
    No paper-specific finding is recorded.
    PMID 20104584 ↗
  • An integrated in silico approach to analyze the involvement of single amino acid polymorphisms in FANCD1/BRCA2-PALB2 and FANCD1/BRCA2-RAD51 complex.
    Doss CG et al. · 2014
    No paper-specific finding is recorded.
    PMID 24817641 ↗
  • Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.
    Wong-Brown MW et al. · 2015
    No paper-specific finding is recorded.
    PMID 25682074 ↗
  • Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
    No paper-specific finding is recorded.
    PMID 25741868 ↗
  • A Standardized DNA Variant Scoring System for Pathogenicity Assessments in Mendelian Disorders.
    No paper-specific finding is recorded.
    PMID 26467025 ↗
  • Clinical Next-Generation Sequencing Pipeline Outperforms a Combined Approach Using Sanger Sequencing and Multiplex Ligation-Dependent Probe Amplification in Targeted Gene Panel Analysis.
    Schenkel LC et al. · 2016
    Schenkel et al. (J Mol Diagn 2016) clinically validated a targeted NGS pipeline for BRCA1/BRCA2 and, in a prospective cohort of 240 hereditary breast/ovarian cancer patients, detected BRCA2 c.10111A>G p.Thr3371Ala as a heterozygous missense variant in 1 patient (confirmed by Sanger sequencing). The paper reports no parental testing, no de novo assessment, and no family segregation or non-segregation data for this variant; it establishes only that the variant occurs as a heterozygous germline finding in an affected HBOC proband. For the segregation/de novo group this means the literature contains no informative meioses, no de novo occurrence, and no segregation LR for c.10111A>G.
    Names this variant
    PMID 27376475 ↗
    Quoted passage
    BRCA2 1 Missense c.10111A>G p.Thr3371Ala HZ

    Table 2 (BRCA Mutations Identified in the Prospective Cohort, n = 240), BRCA2 section

  • American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    No paper-specific finding is recorded.
    PMID 12692171 ↗
  • PAX6 Aniridia Syndrome.
    No paper-specific finding is recorded.
    PMID 20301534 ↗
  • Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.
    No paper-specific finding is recorded.
    PMID 28492532 ↗

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 1.05323e-05; MAF= 0.00105%, 17/1614084 alleles, homozygotes = 0) and has highest observed frequency in the East Asian population (AF= 0.000200454; MAF= 0.02005%, 9/44898 alleles, homozygotes = 0); grpmax FAF= 0.00010391.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 7.07504e-06; MAF= 0.00071%, 2/282684 alleles, homozygotes = 0) and has highest observed frequency in the East Asian population (AF= 0.000100241; MAF= 0.01002%, 2/19952 alleles, homozygotes = 0).

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 0.00043426338074041906, 8/18422 alleles, homozygotes = 0).

ClinVar

This variant has been reported in ClinVar as Likely benign (9 clinical laboratories) and as Uncertain significance (2 clinical laboratories) and as Benign (2 clinical laboratories). (ClinVarID = 37720)

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.05). REVEL score = 0.093. BayesDel score = -0.538317.

Functional

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. BRCA2, a tumor suppressor involved in the DNA damage response, is mutated in various cancer types.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has previously been reported in somatic cancers (COSMIC; COSV116004818, n = 2 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.